Etamycin as a Novel Mycobacterium abscessus Inhibitor

The increase in drug-resistant , which has become resistant to existing standard-of-care agents, is a major concern, and new antibacterial agents are strongly needed. In this study, we introduced etamycin that showed an excellent activity against . We found that etamycin significantly inhibited the...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2020-09, Vol.21 (18), p.6908
Main Authors: Hanh, Bui Thi Bich, Kim, Tae Ho, Park, June-Woo, Lee, Da-Gyum, Kim, Jae-Sung, Du, Young Eun, Yang, Chul-Su, Oh, Dong-Chan, Jang, Jichan
Format: Article
Language:English
Subjects:
Animals
drug resistance
Female
Fish Diseases - drug therapy
Fish Diseases - microbiology
Macrolides - pharmacology
Mice
Mycobacterium abscessus
Mycobacterium abscessus - growth & development
Mycobacterium Infections, Nontuberculous - drug therapy
novel drug discovery
Zebrafish - microbiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The increase in drug-resistant , which has become resistant to existing standard-of-care agents, is a major concern, and new antibacterial agents are strongly needed. In this study, we introduced etamycin that showed an excellent activity against . We found that etamycin significantly inhibited the growth of wild-type strain, three subspecies, and clinical isolates in vitro and inhibited the growth of that resides in macrophages without cytotoxicity. Furthermore, the in vivo efficacy of etamycin in the zebrafish ( ) infection model was greater than that of clarithromycin, which is recommended as the core agent for treating infections. Thus, we concluded that etamycin is a potential anti- candidate for further development as a clinical drug candidate.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms21186908